Cimzia Insurance Denied? How to Appeal Your Certolizumab Denial

Cimzia (certolizumab pegol) is a PEGylated anti-TNF biologic approved for rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and plaque psoriasis. It has the unique distinction of being the only anti-TNF biologic found to have negligible placental transfer, making it particularly relevant for patients of childbearing age. Despite its broad FDA approvals, insurance companies routinely deny Cimzia. Here's how to appeal.

What Cimzia Treats and Why Patients Need It

Cimzia is a Fc-free, PEGylated anti-TNF biologic. FDA-approved for:

• Moderate-to-severe rheumatoid arthritis
• Moderate-to-severe Crohn's disease
• Active psoriatic arthritis
• Active ankylosing spondylitis and non-radiographic axial spondyloarthritis (nr-axSpA)
• Moderate-to-severe plaque psoriasis

The Fc-free structure minimizes certain immune reactions, and the PEGylation prolongs half-life. Most importantly, its unique pharmacokinetic profile results in minimal placental transfer — confirmed in the CRIB study — making it the preferred anti-TNF for patients who are pregnant or planning pregnancy.

For patients with inflammatory arthritis, Crohn's, or spondyloarthritis who have failed conventional disease-modifying therapy (DMARDs), Cimzia provides targeted anti-TNF therapy that can achieve remission or low disease activity and prevent irreversible joint damage.

Common Denial Reasons for Cimzia

Step therapy requirements: Most plans require failure of conventional DMARDs (methotrexate, sulfasalazine, hydroxychloroquine for RA; steroids and immunomodulators like 6-MP for Crohn's) before any biologic is approved.

Preferred TNF inhibitor not tried first: Plans frequently have one or two preferred anti-TNF agents (Humira, Enbrel, or their biosimilars) and require those to be tried before Cimzia. This is especially problematic if the patient has a clinical reason to prefer Cimzia specifically.

Indication-specific denial: Some plans have different formulary coverage for each indication. Cimzia may be covered for RA but not Crohn's, or vice versa, depending on the plan structure.

Pregnancy-related request without complete documentation: Patients requesting Cimzia specifically because of pregnancy or family planning may not receive coverage without documented discussion and specialist support in the medical record.

Step-by-Step: How to Appeal a Cimzia Denial

Step 1: Identify the denial reason. Step therapy, preferred formulary agent, or indication-specific exclusion?

Step 2: Document your DMARD history. For RA: methotrexate, leflunomide, hydroxychloroquine trials with dates, doses, duration, and reasons for failure. For Crohn's: 5-ASA, steroids, azathioprine, 6-MP, methotrexate trials.

Step 3: Have your rheumatologist or gastroenterologist write a Letter of Medical Necessity addressing your diagnosis, disease severity (DAS28, CDAI/Harvey-Bradshaw, BASDAI for AS), prior treatments, and why Cimzia is the appropriate anti-TNF choice.

Step 4: If the reason for preferring Cimzia is pregnancy, document this explicitly. Include the specialist's statement that Cimzia's negligible placental transfer makes it the medically preferred choice for this patient's reproductive situation, with reference to the CRIB study.

Step 5: If denied in favor of a preferred TNF inhibitor, document any clinical reason Cimzia is preferable — prior intolerance to the preferred agent, prior failure, dosing advantages, or the pregnancy rationale.

Step 6: File the internal appeal and request peer-to-peer review.

Step 7: File an external appeal if needed.

What to Include in Your Cimzia Appeal Letter

• Member information and claim reference
• Cimzia (certolizumab pegol) prescribed dose and indication
• Disease activity documentation: DAS28 for RA, CDAI/Harvey-Bradshaw for Crohn's, BASDAI for AS, BSA/IGA for psoriasis
• Prior DMARD history with dates, doses, outcomes, and reasons for discontinuation
• Prior biologic history if applicable
• Letter of Medical Necessity from rheumatologist, gastroenterologist, or dermatologist
• If pregnancy-related: CRIB study citation and physician statement on placental transfer
• FDA approval documentation for the specific indication
• ACR, ECCO, or EULAR guideline citations supporting biologic therapy after DMARD failure
• Request for peer-to-peer review

Success Tips for Cimzia Appeals

Lead with the pregnancy advantage when relevant. If you are pregnant or planning pregnancy, Cimzia's negligible placental transfer — documented in the CRIB pharmacokinetic study — is a clinically compelling and medically specific reason to prefer Cimzia over other TNF inhibitors. This is a case where Cimzia isn't interchangeable, and the appeal should make that clear.

Document prior anti-TNF failures specifically. If you've already tried and failed Humira or Enbrel (the typically preferred agents), this is the strongest argument for Cimzia. Include the specific drug, dose, duration, and reason for failure (lack of efficacy, adverse effects).

Quantify disease activity. Validated disease activity scores — DAS28 for RA, BASDAI for AS, CDAI for Crohn's — are the language insurers understand. Include current and historical scores to show inadequate disease control.

Know your indication. The appeal for Cimzia in nr-axSpA is distinct from the RA appeal. Nr-axSpA has fewer treatment options and no approved conventional DMARD, making biologic therapy more clearly the standard of care.

Fight Back With ClaimBack

You and your doctor chose Cimzia for a reason. An insurance denial shouldn't override that clinical judgment. ClaimBack helps you build a compelling, well-documented appeal to fight back against unjust denials.

Start your Cimzia appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied